German Cell Therapy Achieves Autoimmune Remission

Scientists reported that a 47-year-old woman in Germany entered sustained remission from three severe autoimmune diseases after receiving CAR T-cell therapy. The case was described in the journal Med on April 9, 2026. Researchers said it is the first documented instance in which this form of cell therapy has successfully addressed multiple autoimmune conditions at the same time.

 

The patient had lived for more than a decade with autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APS). According to the report, she had already gone through nine prior treatments without achieving durable control. Her condition required daily blood transfusions and ongoing use of permanent blood thinning medication, underscoring the severity and complexity of her disease burden.

 

Researchers at University Hospital Erlangen administered the CAR T-cell therapy. The approach involves collecting a patient’s T-cells and engineering them to recognize and eliminate B-cells that carry the CD19 protein. The scientists said the targeted B-cells were responsible for producing harmful antibodies, and that removing them aimed to interrupt the autoimmune process driving the patient’s conditions.

 

Within weeks of treatment, the team reported that all three diseases showed a response. The patient then reached a treatment-free remission for 14 months, according to the publication. The researchers described the outcome as an immune “reset,” noting that when B-cells later regenerated, they appeared healthy rather than producing the damaging antibodies seen before therapy.

 

The report also described ongoing clinical findings that remain relevant for safety monitoring. The patient continues to have a low white blood cell count and slightly elevated liver enzymes. Researchers attributed these abnormalities to the effects of earlier treatments rather than to the CAR T-cell therapy itself, as presented in the case description.

 

is that a single, targeted immune-cell intervention may have potential as a new therapeutic avenue for patients with complex autoimmune disorders that do not respond to standard care. However, the scientists emphasized that clinical trials are needed to evaluate how durable the remission is over longer periods and whether similar results can be achieved across a broader range of autoimmune diseases.

 

Until such trials are completed, the evidence remains limited to this documented case and its follow-up period.